
Hims & Hers Stock Navigates Credibility Test Ahead of Key FDA Decision
Hims & Hers faces a pivotal week as investors weigh its explosive revenue growth against collapsing earnings estimates and concerns over customer retention, with a critical FDA meeting on peptides set to be a major catalyst.







